SyneuRx International (Taiwan) Corp. Share Price
Equities
6575
TW0006575004
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.2 TWD | -.--% |
|
-.--% | -.--% |
Sales 2022 | - | Sales 2023 | 1.32 42.76 110.49 | Capitalization | 2.33B 75.26B 194B |
---|---|---|---|---|---|
Net income 2022 | -353M -11.42B -29.5B | Net income 2023 | -133M -4.3B -11.12B | EV / Sales 2022 | - |
Net cash position 2022 | 48.6M 1.57B 4.06B | Net cash position 2023 | 87.71M 2.84B 7.33B | EV / Sales 2023 | 1,69,35,94,981 x |
P/E ratio 2022 |
-5.89
x | P/E ratio 2023 |
-17.1
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 80.14% |
![Extreme 8.36](/images/extremecours_fleche.png)
![Extreme 8.36](/images/extremecours_fleche.png)
![Extreme 8.36](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Kuo Chuan Tsai
CEO | Chief Executive Officer | - | 02/13/02 |
I Chen Yan
DFI | Director of Finance/CFO | - | 11/16/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mao Chung Chang
BRD | Director/Board Member | - | 01/20/01 |
Kuo Chuan Tsai
CEO | Chief Executive Officer | - | 02/13/02 |
Cheng Wen Wu
BRD | Director/Board Member | - | 26/17/26 |
1st Jan change | Capi. | |
---|---|---|
-.--% | 71.77M | |
+14.73% | 121B | |
+17.19% | 112B | |
+3.20% | 22.57B | |
-18.45% | 20.82B | |
-15.40% | 16.3B | |
-16.87% | 16.19B | |
-42.36% | 16.17B | |
+1.02% | 13.17B | |
+22.94% | 11.11B |
- Stock Market
- Equities
- 6575 Stock